A Phase 2 interventional study of Pacritinib and Placebo in COVID19, COVID-19 and COVID, sponsored by CTI BioPharma. Terminated at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-05.
Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 480th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 371st registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
This study is registered under CTI BioPharma, one of the names counted as Swedish Orphan Biovitrum. Under that name alone:
CTI BioPharma is the lead sponsor of 38 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Swedish Orphan Biovitrum has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer. Severe COVID-19 is defined as confirmed disease in patients who are hospitalized with hypoxia (blood oxygen saturation [SpO2] ≤93% on room air at sea level), respiratory rate >30, arterial oxygen partial pressure [PaO2]/ fraction of inspired oxygen [FiO2] \<300, or lung infiltrates >50% but do not require IMV.
Patients will be randomized 1:1 to receive pacritinib (400 mg once daily [QD] on Day 1, then 200 mg twice daily [BID] from Day 2 to Day 14) + SOC or placebo + SOC.
Assigned treatment will continue for up to Day 14 or until the patient experiences intolerable adverse events (AEs), withdraws consent, or initiates another investigational therapy or until the study is terminated. Assigned therapy may be given for an additional 7 days (for a total of 21 days) with the approval of the Medical Monitor if, in the opinion of the investigator, the patient's clinical signs and symptoms are improving and the potential benefit outweighs the potential risk.In the event of hospital discharge, patients will complete treatment with the assigned therapy as an outpatient.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pacritinib 400 mg once daily \[QD\] on Day 1, then 200 mg twice daily \[BID\] from Day 2 to Day 14) + SOC
Drug: Pacritinib
4 capsules once daily \[QD\] on Day 1, then 2 capsules twice daily \[BID\] from Day 2 to Day 14) + SOC
Drug: Placebo
100 mg capsules
Also known as: SB1518, Oral Jak Inhibitor, Oral Irak inhibitor, Oral Csf1 inhibitor
Placebo capsules matching pacritinib 100 mg capsules
Percentage of Participants With Progression to IMV and/or ECMO or Death
The percentage is calculated as the number of patients who progress to IMV/ECMO or death divided by the total number of patients in the ITT population (n/N \* 100).
Time frame: Baseline to Day 28
The Number of Ventilator-Free Days
the number of days that patients are alive and not intubated, from randomization to Day 28
Time frame: Baseline to Day 28
The Mortality Rate at Day 28
the number of patients with outcome of death during the 28 days following randomization
Time frame: Baseline to Day 28
The Mortality Rate at Day 15
the number of patients with outcome of death in the 15 days following randomization
Time frame: Baseline to Day 15
The Time to Improvement by at Least 2 Points Relative to Baseline on the 7-point Ordinal Scale of Clinical Status
Time to Improvement (days) = Date of improvement - Date of randomization + 1. Date of Improvement was defined as the time to first ordinal scale assessment 2 points or more lower than the baseline clinical status assessment.
Time frame: Baseline, Day 8, 15, 22, and 28.
The Clinical Status as Assessed by the 7-point Ordinal Scale of Clinical Status at Days 8, 15, 22, and 28
Clinical status assessment based on the adapted scale from Cao et al. The patient CS is summarized by study visit. STATUS: 1. not hospitalized with resumption of normal activities; 2. not hospitalized but unable to resume normal activities; 3. hospitalization, not requiring supplemental oxygen; 4. hospitalization, requiring supplemental oxygen not meeting the criteria for categories 5 or 6; 5. hospitalization, on non-invasive positive pressure ventilation or high-flow nasal cannula; 6. hospitalization, requiring IMV and/or ECMO; 7. death.
Time frame: Baseline, Day 8, 15, 22, 28
The Rate of Use of Immunomodulatory Agents as Treatment for COVID-19
the proportion of patients reporting use of medications such as corticosteroids, tocilizumab, anakinra, or eculizumab as treatment for COVID-19, during 28 days following randomization
Time frame: Baseline to Day 28
| Milestone | Pacritinib and SOC | Placebo and SOC |
|---|---|---|
| Started | 99 | 101 |
| Completed | 68 | 80 |
| Not completed | 31 | 21 |
| Withdrew: Death | 12 | 12 |
| Withdrew: Withdrawal by subject | 13 | 5 |
| Withdrew: Lost to follow-up | 6 | 3 |
| Withdrew: Patient hospitalized and was nonverbal at the end of the study | 0 | 1 |
The percentage is calculated as the number of patients who progress to IMV/ECMO or death divided by the total number of patients in the ITT population (n/N \* 100).
| Participants | Pacritinib and SOC | Placebo and SOC |
|---|---|---|
| Percentage of Participants With Progression to IMV and/or ECMO or Death | 26 | 25 |
the number of days that patients are alive and not intubated, from randomization to Day 28
| days | Pacritinib and SOC | Placebo and SOC |
|---|---|---|
| The Number of Ventilator-Free Days | 22.1 ± 10.2 | 22.6 ± 9.35 |
the number of patients with outcome of death during the 28 days following randomization
| % of patients with outcome of death /D28 | Pacritinib and SOC | Placebo and SOC |
|---|---|---|
| The Mortality Rate at Day 28 | 10.1 (5.0 to 17.8) | 7.9 (3.5 to 15.0) |
the number of patients with outcome of death in the 15 days following randomization
| % of patients with outcome of death /D15 | Pacritinib and SOC | Placebo and SOC |
|---|---|---|
| The Mortality Rate at Day 15 | 5.1 (1.7 to 11.4) | 4.0 (1.1 to 9.8) |
Time to Improvement (days) = Date of improvement - Date of randomization + 1. Date of Improvement was defined as the time to first ordinal scale assessment 2 points or more lower than the baseline clinical status assessment.
| days | Pacritinib and SOC | Placebo and SOC |
|---|---|---|
| The Time to Improvement by at Least 2 Points Relative to Baseline on the 7-point Ordinal Scale of Clinical Status | 9.0 (8.0 to 10.0) | 9.0 (7.0 to 11.0) |
Clinical status assessment based on the adapted scale from Cao et al. The patient CS is summarized by study visit. STATUS: 1. not hospitalized with resumption of normal activities; 2. not hospitalized but unable to resume normal activities; 3. hospitalization, not requiring supplemental oxygen; 4. hospitalization, requiring supplemental oxygen not meeting the criteria for categories 5 or 6; 5. hospitalization, on non-invasive positive pressure ventilation or high-flow nasal cannula; 6. hospitalization, requiring IMV and/or ECMO; 7. death.
| participants | Pacritinib and SOC | Placebo and SOC |
|---|---|---|
| Day 8 : Clinical status 1 | 15 | 11 |
| Day 8 : Clinical status 2 | 23 | 37 |
| Day 8 : Clinical status 3 | 5 | 3 |
| Day 8 : Clinical status 4 | 20 | 11 |
| Day 8 : Clinical status 5 | 15 | 20 |
| Day 8 : Clinical status 6 | 9 | 14 |
| Day 8 : Clinical status 7 | 0 | 1 |
| Day 8 : Clinical status Missing | 12 | 4 |
| Day 15: Clinical status 1 | 19 | 17 |
| Day 15: Clinical status 2 | 43 | 47 |
| Day 15: Clinical status 3 | 1 | 1 |
| Day 15: Clinical status 4 | 2 | 8 |
| Day 15: Clinical status 5 | 5 | 2 |
| Day 15: Clinical status 6 | 10 | 16 |
| Day 15: Clinical status 7 | 0 | 2 |
| Day 15: Clinical status Missing | 19 | 8 |
| Day 22: Clinical status 1 | 27 | 24 |
| Day 22: Clinical status 2 | 36 | 48 |
| Day 22: Clinical status 3 | 1 | 0 |
| Day 22: Clinical status 4 | 0 | 1 |
| Day 22: Clinical status 5 | 4 | 1 |
| Day 22: Clinical status 6 | 7 | 12 |
| Day 22: Clinical status 7 | 3 | 1 |
| Day 22: Clinical status Missing | 21 | 14 |
| Day 28: Clinical status 1 | 31 | 30 |
| Day 28: Clinical status 2 | 32 | 42 |
| Day 28: Clinical status 3 | 0 | 0 |
| Day 28: Clinical status 4 | 3 | 2 |
| Day 28: Clinical status 5 | 2 | 1 |
| Day 28: Clinical status 6 | 6 | 10 |
| Day 28: Clinical status 7 | 0 | 1 |
| Day 28: Clinical status Missing | 25 | 15 |
the proportion of patients reporting use of medications such as corticosteroids, tocilizumab, anakinra, or eculizumab as treatment for COVID-19, during 28 days following randomization
| Participants | Pacritinib and SOC | Placebo and SOC |
|---|---|---|
| The Rate of Use of Immunomodulatory Agents as Treatment for COVID-19 | 97 | 96 |
Collected over Daily (Days 2 through 28), End of Treatment (for inpatients only), Day of hospital discharge, Weekly outpatient assessment (to evaluate daily AEs), 30-day Post End of Treatment. AE data were collected from the time of randomization through 30 days following the last dose of pacritinib/placebo.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pacritinib and SOC | 12/96 (12.5%) | 20/96 (20.8%) | 74/96 (77.1%) |
| Placebo and SOC | 12/101 (11.9%) | 33/101 (32.7%) | 79/101 (78.2%) |
| Event | Pacritinib and SOC | Placebo and SOC |
|---|---|---|
| respiratory failureRespiratory, thoracic and mediastinal disorders | 7/96 | 15/101 |
| acute respiratory failureRespiratory, thoracic and mediastinal disorders | 6/96 | 8/101 |
| hypoxiaRespiratory, thoracic and mediastinal disorders | 4/96 | 6/101 |
| septic shockInfections and infestations | 2/96 | 6/101 |
| acute kidney injuryRenal and urinary disorders | 3/96 | 3/101 |
| acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 3/96 | 0/101 |
| cardiac arrestCardiac disorders | 1/96 | 3/101 |
| pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/96 | 3/101 |
| hypotensionCardiac disorders | 2/96 | 1/101 |
| cardio-respiratory arrestCardiac disorders | 2/96 | 0/101 |
| Event | Pacritinib and SOC | Placebo and SOC |
|---|---|---|
| anaemiaBlood and lymphatic system disorders | 12/96 | 18/101 |
| Alanine aminotransferase increasedHepatobiliary disorders | 15/96 | 17/101 |
| bradycardiaCardiac disorders | 15/96 | 11/101 |
| constipationGastrointestinal disorders | 12/96 | 13/101 |
| hypokalaemiaMetabolism and nutrition disorders | 12/96 | 12/101 |
| diarrhoeaGastrointestinal disorders | 12/96 | 4/101 |
| hyperkalaemiaMetabolism and nutrition disorders | 9/96 | 11/101 |
| hyperglycaemiaMetabolism and nutrition disorders | 3/96 | 11/101 |
| acute kidney injuryRenal and urinary disorders | 9/96 | 7/101 |
| Aspartate aminotransferase increasedHepatobiliary disorders | 9/96 | 6/101 |
| Age, Continuous(years) | Pacritinib and SOC | Placebo and SOC | Total |
|---|---|---|---|
| Median | 60.0 (19 to 87) | 59.0 (28 to 94) | 60.0 (19 to 94) |
| Age, Customized(Participants) | Pacritinib and SOC | Placebo and SOC | Total |
|---|---|---|---|
| Age group — <60 years | 48 | 51 | 99 |
| Age group — ≥60 years | 51 | 50 | 101 |
| Sex: Female, Male(Participants) | Pacritinib and SOC | Placebo and SOC | Total |
|---|---|---|---|
| Female | 43 | 37 | 80 |
| Male | 56 | 64 | 120 |
| Ethnicity (NIH/OMB)(Participants) | Pacritinib and SOC | Placebo and SOC | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 14 | 27 |
| Not Hispanic or Latino | 79 | 81 | 160 |
| Unknown or Not Reported | 7 | 6 | 13 |
| Race (NIH/OMB)(Participants) | Pacritinib and SOC | Placebo and SOC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 2 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 17 | 19 | 36 |
| White | 74 | 72 | 146 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 6 | 11 |
| Region of Enrollment(participants) | Pacritinib and SOC | Placebo and SOC | Total |
|---|---|---|---|
| United States | 99 | 101 | 200 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2020 to primary completion in Sep 2021, 15 months.
Results were first posted in Jun 2024, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pacritinib